Cadila receives Final USFDA Nod For Phentermine Hydrochloride


Zydus Cadila has received the final approval from the USFDA to market Phentermine Hydrochloride orally disinterating tablets in strengths of 15mg, 30 mg and 37.5 mg.

The drug is used together with diet and exercise to treat obesity in people with risk factors such as high blood pressure, high cholesterol or diabetes and will be produced at the group’s formulations manufacturing facility at Moraiya in Ahmedabad.

The group now has more than 120 approvals and so far has filled over 300 ANDAs, since the commencement of the filing process in FY 2003-04.

The stock of Cadila was trading at Rs 526.25 per share, higher by Rs 5.30 per share or 1% at 1035 hours. It has delivered 60% returns in a period of one year and has outperformed the BSE Sensex and BSE Healthcare indices over the same time span.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.co
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: